Lenvima for Renal Cell Carcinoma – Details

Details

Files
Generic Name:
Lenvatinib
Project Status:
Complete
Therapeutic Area:
Renal Cell Carcinoma (RCC)
Manufacturer:
Eisai Limited
Brand Name:
Lenvima
Project Line:
Reimbursement Review
Project Number:
PC0140 -000
Performance Metric:
Achieved
Strength:
4mg and 10mg
Tumour Type:
Genitourinary
Indications:
Renal Cell Carcinoma (RCC)
Funding Request:
In combination with everolimus for the treatment of patients with advanced or metastatic, clear-cell RCC following one prior VEGF-targeted therapy.
Sponsor:
Eisai Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.